238 related articles for article (PubMed ID: 30911112)
1. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
2. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
3. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
4. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
5. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
6. The new tool "
Shomali W; Gotlib J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
[TBL] [Abstract][Full Text] [Related]
7. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
8. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
[TBL] [Abstract][Full Text] [Related]
9. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
10. Avapritinib for advanced systemic mastocytosis.
Gotlib J; Reiter A; DeAngelo DJ
Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
12. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
13. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
15. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
[TBL] [Abstract][Full Text] [Related]
16. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
17. Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2016 Apr; 96(4):381-8. PubMed ID: 26095448
[TBL] [Abstract][Full Text] [Related]
18. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
19. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
[TBL] [Abstract][Full Text] [Related]
20. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
